Skip to main content
Top
Published in: BMC Urology 1/2013

Open Access 01-12-2013 | Research article

The natural history of secondary muscle-invasive bladder cancer

Authors: Guy Hidas, Dov Pode, Amos Shapiro, Ran Katz, Liat Appelbaum, Galina Pizov, Kevin C Zorn, Ezekiel H Landau, Mordechai Duvdevani, Ofer N Gofrit

Published in: BMC Urology | Issue 1/2013

Login to get access

Abstract

Background

The management of patients with high-grade non muscle invasive bladder cancer (NMIBC) brings diagnostic and therapeutic challenges. In the current study, we sought to study the natural history of progression to "secondary" muscle-invasive bladder cancer (MIBC)-cancer that developed during follow up of patients presenting with non-muscle invasive bladder cancer (NMIBC).

Methods

Between 1998 and 2008, 760 patients were treated for bladder cancer. Primary MIBC (>=T2) tumors (present upon presentation) were diagnosed in 114 patients. All patients with high-grade NMIBC were treated with intravesical BCG. Mean follow-up was 44 months.

Results

Forty patients (6.1%) developed secondary MIBC after a mean period of 21 months from initial diagnosis of bladder cancer. The 2- and 5-year disease-specific survival rates were better for patients with secondary MIBC (90% and 56% compared to 69% and 42% for patients with primary disease, p=0.03). The Kaplan-Meier curves of the two groups were parallel but displaced by approximately 2 years.

Conclusion

In the current series, MIBC progression occurred among initially presenting patients with NMIBC in 6.1%. In most patients, the initial diagnosis of NMIBC is correct and muscle invasion occurs after a mean period of about 2 years. This supports a non-radical approach in patients with high-grade T1, Ta or Tis. Meticulous follow-up with liberal biopsy of any suspicious lesion may provide early diagnosis of invasive disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Ward E: Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007, 99 (18): 1384-1394. 10.1093/jnci/djm127.CrossRefPubMed Jemal A, Siegel R, Ward E: Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007, 99 (18): 1384-1394. 10.1093/jnci/djm127.CrossRefPubMed
2.
go back to reference Stein JP, Penson DF: Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int. 2008, 102 (3): 270-275. 10.1111/j.1464-410X.2008.07743.x.CrossRefPubMed Stein JP, Penson DF: Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int. 2008, 102 (3): 270-275. 10.1111/j.1464-410X.2008.07743.x.CrossRefPubMed
3.
go back to reference Mhawech-Fauceglia P, Cheney RT, Schwaller J: Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006, 106 (6): 1205-1216. 10.1002/cncr.21743.CrossRefPubMed Mhawech-Fauceglia P, Cheney RT, Schwaller J: Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006, 106 (6): 1205-1216. 10.1002/cncr.21743.CrossRefPubMed
4.
go back to reference Herr HW: Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 1997, 15 (2): 84-88. 10.1007/BF02201977.CrossRefPubMed Herr HW: Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 1997, 15 (2): 84-88. 10.1007/BF02201977.CrossRefPubMed
5.
go back to reference Shahin O, Thalmann GN, Rentsch C: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003, 169 (1): 96-100. 10.1016/S0022-5347(05)64044-X.CrossRefPubMed Shahin O, Thalmann GN, Rentsch C: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003, 169 (1): 96-100. 10.1016/S0022-5347(05)64044-X.CrossRefPubMed
6.
go back to reference Peyromaure M, Zerbib M: T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int. 2004, 93 (1): 60-63. 10.1111/j.1464-410X.2004.04556.x.CrossRefPubMed Peyromaure M, Zerbib M: T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int. 2004, 93 (1): 60-63. 10.1111/j.1464-410X.2004.04556.x.CrossRefPubMed
7.
go back to reference Babjuk M, Oosterlinck W, Sylvester R: European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008, 54 (2): 303-314. 10.1016/j.eururo.2008.04.051.CrossRefPubMed Babjuk M, Oosterlinck W, Sylvester R: European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008, 54 (2): 303-314. 10.1016/j.eururo.2008.04.051.CrossRefPubMed
8.
go back to reference Herr HW, Wartinger DD, Fair WR: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol. 1992, 147 (4): 1020-1023.PubMed Herr HW, Wartinger DD, Fair WR: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol. 1992, 147 (4): 1020-1023.PubMed
9.
go back to reference Stein JP, Lieskovsky G, Cote R: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001, 19 (3): 666-675.PubMed Stein JP, Lieskovsky G, Cote R: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001, 19 (3): 666-675.PubMed
10.
go back to reference Cheng L, Weaver AL, Leibovich BC: Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000, 88 (10): 2326-2332. 10.1002/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T.CrossRefPubMed Cheng L, Weaver AL, Leibovich BC: Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000, 88 (10): 2326-2332. 10.1002/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T.CrossRefPubMed
11.
go back to reference Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol. 2001, 166 (4): 1296-1299. 10.1016/S0022-5347(05)65756-4.CrossRefPubMed Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol. 2001, 166 (4): 1296-1299. 10.1016/S0022-5347(05)65756-4.CrossRefPubMed
12.
go back to reference Schrier BP, Hollander MP, van Rhijn BWG: Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol. 2004, 45 (3): 292-296. 10.1016/j.eururo.2003.10.006.CrossRefPubMed Schrier BP, Hollander MP, van Rhijn BWG: Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol. 2004, 45 (3): 292-296. 10.1016/j.eururo.2003.10.006.CrossRefPubMed
13.
go back to reference May M, Helke C, Nitzke T: Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004, 72 (2): 103-111. 10.1159/000075962.CrossRefPubMed May M, Helke C, Nitzke T: Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004, 72 (2): 103-111. 10.1159/000075962.CrossRefPubMed
14.
go back to reference Ferreira U, Matheus WE, Nardi Pedro R: Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate. Urol Int. 2007, 79 (3): 200-203. 10.1159/000107950.CrossRefPubMed Ferreira U, Matheus WE, Nardi Pedro R: Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate. Urol Int. 2007, 79 (3): 200-203. 10.1159/000107950.CrossRefPubMed
15.
go back to reference Vaidya A, Soloway MS, Hawke C: De novo muscle invasive bladder cancer: is there a change in trend?. J Urol. 2001, 165 (1): 47-50. 10.1097/00005392-200101000-00012.CrossRefPubMed Vaidya A, Soloway MS, Hawke C: De novo muscle invasive bladder cancer: is there a change in trend?. J Urol. 2001, 165 (1): 47-50. 10.1097/00005392-200101000-00012.CrossRefPubMed
16.
go back to reference Mostofi FK, Sobin LH, Torloni H: International histological classification of tumours, No 10. Histological typing of urinary bladder tumours. 1973, Geneva: World Health Organization Mostofi FK, Sobin LH, Torloni H: International histological classification of tumours, No 10. Histological typing of urinary bladder tumours. 1973, Geneva: World Health Organization
17.
go back to reference Sylvester RJ, Van Der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002, 168 (5): 1964-1970. 10.1016/S0022-5347(05)64273-5.CrossRefPubMed Sylvester RJ, Van Der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002, 168 (5): 1964-1970. 10.1016/S0022-5347(05)64273-5.CrossRefPubMed
18.
go back to reference Bianco FJ, Justa D, Grignon DJ: Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004, 22 (4): 290-294. 10.1016/S1078-1439(03)00144-3.CrossRefPubMed Bianco FJ, Justa D, Grignon DJ: Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004, 22 (4): 290-294. 10.1016/S1078-1439(03)00144-3.CrossRefPubMed
19.
go back to reference Nieder AM, Simon MA, Kim SS: Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology. 2006, 67 (4): 737-741. 10.1016/j.urology.2005.10.012.CrossRefPubMed Nieder AM, Simon MA, Kim SS: Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology. 2006, 67 (4): 737-741. 10.1016/j.urology.2005.10.012.CrossRefPubMed
Metadata
Title
The natural history of secondary muscle-invasive bladder cancer
Authors
Guy Hidas
Dov Pode
Amos Shapiro
Ran Katz
Liat Appelbaum
Galina Pizov
Kevin C Zorn
Ezekiel H Landau
Mordechai Duvdevani
Ofer N Gofrit
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2013
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-13-23

Other articles of this Issue 1/2013

BMC Urology 1/2013 Go to the issue